17-alpha-hydroxyprogesterone has been researched along with Weight Gain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, H; Dunaif, A; Fogel, N; Grebe, SK; Singh, RJ; Taylor, RL | 1 |
| Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP | 1 |
1 trial(s) available for 17-alpha-hydroxyprogesterone and Weight Gain
| Article | Year |
|---|---|
A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Bone Development; Child; Child, Preschool; Dehydroepiandrosterone; Female; Flutamide; Humans; Hydrocortisone; Infant; Male; Seasons; Testolactone; Weight Gain | 1996 |
1 other study(ies) available for 17-alpha-hydroxyprogesterone and Weight Gain
| Article | Year |
|---|---|
Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androgens; Androstenedione; Birth Weight; Body Mass Index; Body Size; Case-Control Studies; Estradiol; Female; Fetal Blood; Gestational Age; Humans; Infant, Newborn; Infant, Small for Gestational Age; Male; Maternal Age; Polycystic Ovary Syndrome; Reference Values; Weight Gain; Young Adult | 2010 |